{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:15Z","timestamp":1789560135823,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the key research and development Plan Project of the Department of Science and Technology of Shaanxi Province","award":["2020GXLH-Y-004"],"award-info":[{"award-number":["2020GXLH-Y-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04460-6","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:46:58Z","timestamp":1782200818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of anti-PD-1-based therapies in advanced melanoma across acral and mucosal subtypes: a nationwide retrospective cohort study"],"prefix":"10.1007","volume":"75","author":[{"given":"Yuan","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltaf","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"1","key":"4460_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jaad.2024.09.035","volume":"92","author":"Y Sun","year":"2025","unstructured":"Sun Y, Shen Y, Liu Q et al (2025) Global trends in melanoma burden: a comprehensive analysis from the global burden of disease study, 1990\u20132021. J Am Acad Dermatol 92(1):100\u2013107","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4460_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.mayocp.2014.02.002","volume":"89","author":"DJ Shah","year":"2014","unstructured":"Shah DJ, Dronca RS (2014) Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 89(4):504\u2013519","journal-title":"Mayo Clin Proc"},{"issue":"33","key":"4460_CR3","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Long GV, Brady B et al (2020) Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol 38(33):3937\u20133946","journal-title":"J Clin Oncol"},{"issue":"10","key":"4460_CR4","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351(10):998\u20131012","journal-title":"N Engl J Med"},{"issue":"9","key":"4460_CR5","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","volume":"15","author":"AM Menzies","year":"2014","unstructured":"Menzies AM, Long GV (2014) Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15(9):e371-381","journal-title":"Lancet Oncol"},{"issue":"1","key":"4460_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si L, Kong Y, Xu X et al (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48(1):94\u2013100","journal-title":"Eur J Cancer"},{"issue":"6165","key":"4460_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1126\/science.1249481","volume":"342","author":"M McNutt","year":"2013","unstructured":"McNutt M (2013) Cancer immunotherapy. Science 342(6165):1417","journal-title":"Science"},{"key":"4460_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","volume":"45","author":"E Kon","year":"2019","unstructured":"Kon E, Benhar I (2019) Immune checkpoint inhibitor combinations: current efforts and important aspects for success. Drug Resist Updat 45:13\u201329","journal-title":"Drug Resist Updat"},{"issue":"4","key":"4460_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582\u2013588","journal-title":"Ann Oncol"},{"issue":"16","key":"4460_CR10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535\u20131546","journal-title":"N Engl J Med"},{"issue":"21","key":"4460_CR11","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309\u20135337","journal-title":"Cell"},{"issue":"1","key":"4460_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ et al (2022) Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 386(1):24\u201334","journal-title":"N Engl J Med"},{"issue":"9","key":"4460_CR13","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde A, Bellasea SL, Kendra KL et al (2023) Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med 29(9):2278\u20132285","journal-title":"Nat Med"},{"issue":"3","key":"4460_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","volume":"23","author":"F Aroldi","year":"2022","unstructured":"Aroldi F, Middleton MR (2022) Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. Am J Clin Dermatol 23(3):331\u2013338","journal-title":"Am J Clin Dermatol"},{"key":"4460_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004668","author":"P Bhave","year":"2022","unstructured":"Bhave P, Ahmed T, Lo SN et al (2022) Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-004668","journal-title":"J Immunother Cancer"},{"issue":"16","key":"4460_CR16","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","volume":"26","author":"B Tang","year":"2020","unstructured":"Tang B, Chi Z, Chen Y et al (2020) Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. Clin Cancer Res 26(16):4250\u20134259","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4460_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","volume":"12","author":"L Si","year":"2019","unstructured":"Si L, Zhang X, Shu Y et al (2019) A phase Ib study of pembrolizumab as second-line therapy for chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol 12(6):828\u2013835","journal-title":"Transl Oncol"},{"issue":"7653","key":"4460_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545(7653):175\u2013180","journal-title":"Nature"},{"issue":"20","key":"4460_CR19","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135\u20132147","journal-title":"N Engl J Med"},{"issue":"32","key":"4460_CR20","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","volume":"37","author":"X Sheng","year":"2019","unstructured":"Sheng X, Yan X, Chi Z et al (2019) Axitinib in combination with toripalimab, a humanized immunoglobulin G(4) monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. J Clin Oncol 37(32):2987\u20132999","journal-title":"J Clin Oncol"},{"key":"4460_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2021.07.018","volume":"156","author":"B Tang","year":"2021","unstructured":"Tang B, Mo J, Yan X et al (2021) Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. Eur J Cancer 156:83\u201392","journal-title":"Eur J Cancer"},{"issue":"8","key":"4460_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaoncol.2023.1363","volume":"9","author":"LL Mao","year":"2023","unstructured":"Mao LL, Lian B, Li CL et al (2023) Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma the CAP 03 phase 2 nonrandomized clinical trial. JAMA Oncol 9(8):1099\u20131107","journal-title":"JAMA Oncol"},{"key":"4460_CR23","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.01.07","author":"Oncology GWCoCSoC","year":"2024","unstructured":"Oncology GWCoCSoC (2024) Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.01.07","journal-title":"Chin J Cancer Res"},{"key":"4460_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115153","volume":"215","author":"C Garbe","year":"2024","unstructured":"Garbe C, Amaral T, Peris K et al (2024) European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2024. Eur J Cancer 215:115153","journal-title":"Eur J Cancer"},{"issue":"9","key":"4460_CR25","doi-asserted-by":"publisher","first-page":"6263","DOI":"10.1007\/s00432-023-04596-3","volume":"149","author":"G Zhu","year":"2023","unstructured":"Zhu G, Shi Q, Zhao B et al (2023) Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study. J Cancer Res Clin Oncol 149(9):6263\u20136269","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"4460_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaoncol.2023.1363","volume":"9","author":"L Mao","year":"2023","unstructured":"Mao L, Lian B, Li C et al (2023) Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial. JAMA Oncol 9(8):1099\u20131107","journal-title":"JAMA Oncol"},{"key":"4460_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010120","author":"SH Kim","year":"2025","unstructured":"Kim SH, Tsao H (2025) Acral melanoma: a review of its pathogenesis, progression, and management. Biomolecules. https:\/\/doi.org\/10.3390\/biom15010120","journal-title":"Biomolecules"},{"issue":"9","key":"4460_CR28","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","volume":"31","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Namikawa K, Yoshino K et al (2020) Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol 31(9):1198\u20131206","journal-title":"Ann Oncol"},{"key":"4460_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2147\/CMAR.S520937","volume":"17","author":"J Zhang","year":"2025","unstructured":"Zhang J, Tian H, Mao L et al (2025) Real-world efficacy and safety of anti-PD-1 antibody plus apatinib and temozolomide for advanced acral melanoma. Cancer Manag Res 17:905\u2013916","journal-title":"Cancer Manag Res"},{"issue":"1","key":"4460_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100949","volume":"14","author":"X Wang","year":"2021","unstructured":"Wang X, Xu W, Chi Z et al (2021) Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Transl Oncol 14(1):100949","journal-title":"Transl Oncol"},{"issue":"12","key":"4460_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/cac2.12119","volume":"40","author":"B Zhang","year":"2020","unstructured":"Zhang B, Qi L, Wang X et al (2020) Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun 40(12):711\u2013720","journal-title":"Cancer Commun"},{"issue":"9","key":"4460_CR32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu S, Wu L, Jian H et al (2022) Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 23(9):1167\u20131179","journal-title":"Lancet Oncol"},{"key":"4460_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004036","author":"S Li","year":"2022","unstructured":"Li S, Wu X, Yan X et al (2022) Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004036","journal-title":"J Immunother Cancer"},{"key":"4460_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack SP, Zhu AX, Wang Y (2020) Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities. Front Immunol 11:598877","journal-title":"Front Immunol"},{"issue":"5","key":"4460_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4460_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","volume":"119","author":"O Hamid","year":"2018","unstructured":"Hamid O, Robert C, Ribas A et al (2018) Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 119(6):670\u2013674","journal-title":"Br J Cancer"},{"issue":"12","key":"4460_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1677139","volume":"8","author":"T Gambichler","year":"2019","unstructured":"Gambichler T, Chatzipantazi M, Schr\u00f6ter U, Stockfleth E, Gedik C (2019) Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. Oncoimmunology 8(12):e1677139","journal-title":"Oncoimmunology"},{"issue":"1","key":"4460_CR38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/annonc\/mdt411","volume":"25","author":"F Egberts","year":"2014","unstructured":"Egberts F, Bergner I, Kr\u00fcger S et al (2014) Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol 25(1):246\u2013250","journal-title":"Ann Oncol"},{"key":"4460_CR39","doi-asserted-by":"crossref","unstructured":"Swetter SM, Johnson D, Albertini MR, et al. (2024) NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2024. J Natl Compr Canc Netw. 22(5):290\u2013298.","DOI":"10.6004\/jnccn.2024.0036"},{"issue":"30","key":"4460_CR40","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H et al (2023) Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol 41(30):4794\u20134820","journal-title":"J Clin Oncol"},{"key":"4460_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","volume":"176","author":"Y Nakamura","year":"2022","unstructured":"Nakamura Y, Namikawa K, Kiniwa Y et al (2022) Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: a retrospective, multicenter study of 254 Japanese patients. Eur J Cancer 176:78\u201387","journal-title":"Eur J Cancer"},{"key":"4460_CR42","doi-asserted-by":"crossref","unstructured":"Bhave P, Ahmed T, Lo SN, et al. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J Immun Cancer. 2022;10(7).","DOI":"10.1136\/jitc-2022-004668"},{"issue":"9","key":"4460_CR43","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2022.06.004","volume":"33","author":"F Dimitriou","year":"2022","unstructured":"Dimitriou F, Namikawa K, Reijers ILM et al (2022) Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol 33(9):968\u2013980","journal-title":"Ann Oncol"},{"issue":"11","key":"4460_CR44","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/1346-8138.15514","volume":"47","author":"K Namikawa","year":"2020","unstructured":"Namikawa K, Kiyohara Y, Takenouchi T et al (2020) Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma. J Dermatol 47(11):1257\u20131266","journal-title":"J Dermatol"},{"issue":"11","key":"4460_CR45","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/1346-8138.15521","volume":"47","author":"A Takahashi","year":"2020","unstructured":"Takahashi A, Namikawa K, Ogata D et al (2020) Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol 47(11):1267\u20131275","journal-title":"J Dermatol"},{"key":"4460_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.02.026","volume":"167","author":"OJ van Not","year":"2022","unstructured":"van Not OJ, de Meza MM, van den Eertwegh AJM et al (2022) Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study. Eur J Cancer 167:70\u201380","journal-title":"Eur J Cancer"},{"key":"4460_CR47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00632","author":"D Davar","year":"2018","unstructured":"Davar D, Wang H, Chauvin JM et al (2018) Phase Ib\/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.18.00632","journal-title":"J Clin Oncol"},{"key":"4460_CR48","doi-asserted-by":"crossref","unstructured":"Dolan M, Shi Y, Mastri M, et al (2024) A senescence-mimicking (senomimetic) VEGFR TKI side-effect primes tumor immune responses via IFN\/STING signaling. Mol Cancer Ther","DOI":"10.1158\/1535-7163.c.7431612"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04460-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:30Z","timestamp":1789556610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04460-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4460"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04460-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"223"}}